European Association for the Study of Diabetes

Obese man measures his waist
#European Association for the Study of Diabetes #GLP-1 #Obesity #Phase I trial #QL Biopharm

QL Biopharm announces new obesity drug results

QL Biopharm, a clinical stage biopharmaceutical company developing biologic drugs for the treatment of metabolic diseases, has shared Phase Ic clinical data for its lead drug candidate ZT002. The data was presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024, Madrid,… Read More

#News #Trending News

Patient using blood pressure monitor
#Cardiovascular disease #European Association for the Study of Diabetes #Type 2 diabetes

Analysis confirms cardiovascular benefits Ozempic

New trial data has shown consistent cardiovascular benefits from Novo Nordisk’s semaglutide in adults with type 2 diabetes, regardless of baseline blood sugar or kidney function. The results show that treatment with Ozempic (once-weekly semaglutide) or Rybelsus (oral semaglutide) demonstrated consistent reductions in major adverse cardiovascular events (MACE) compared with… Read More

#News